Published on 16 Feb 2024 on Zacks via Yahoo Finance
Alnylam Pharmaceuticals ALNY reported a loss of $1.10 per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of $1.20. The company had incurred a loss of $1.68 per share in the year-ago quarter.
The fourth-quarter loss included stock-based compensation expenses, unrealized gain on equity securities and loss on extinguishment of debt. Excluding these items, the adjusted loss was 77 cents per share, narrower than the adjusted loss of $1.39 reported in the year-ago quarter.
Alnylam recorded total revenues of $440 million in the quarter, which missed the Zacks Consensus Estimate of $446 million. In the year-ago quarter, total revenues were $335 million. Net product revenues were $346 million in the reported quarter, up 32% year over year on a reported basis and 30% at constant exchange rate (CER), driven by increased patient numbers for Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran) and the newly approved Amvuttra (vutrisiran).